Meningococcal Factor H-Binding Protein Variants Expressed by Epidemic Capsular Group A, W-135, and X Strains from Africa

被引:67
作者
Beernink, P. T. [1 ]
Caugant, D. A. [2 ]
Welsch, J. A. [1 ]
Koeberling, O. [1 ]
Granoff, D. M. [1 ]
机构
[1] Childrens Hosp Oakland, Res Inst, Ctr Immunobiol & Vaccine Dev, Oakland, CA 94609 USA
[2] Norwegian Inst Publ Hlth, Dept Bacteriol & Immunol, Oslo, Norway
关键词
MEMBRANE VESICLE VACCINE; NEISSERIA-MENINGITIDIS; GROUP-B; SEROGROUP-X; BURKINA-FASO; MONOCLONAL-ANTIBODIES; BACTERICIDAL ACTIVITY; CANDIDATE; IMMUNOGENICITY; IMMUNITY;
D O I
10.1086/597806
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Meningococcal epidemics in Africa are generally caused by capsular group A strains, but W-135 or X strains also cause epidemics in this region. Factor H-binding protein (fHbp) is a novel antigen being investigated for use in group B vaccines. Little is known about fHbp in strains from other capsular groups. Methods. We investigated fHbp in 35 group A, W-135, and X strains from Africa. Results. The 22 group A isolates, which included each of the sequence types (STs) responsible for epidemics since 1963, and 4 group X and 3 group W-135 isolates from recent epidemics had genes encoding fHbp in antigenic variant group 1. The remaining 6 W-135 isolates had fHbp variant 2. Within each fHbp variant group, there was 92%-100% amino acid identity, and the proteins expressed conserved epitopes recognized by bactericidal monoclonal antibodies. Serum samples obtained from mice vaccinated with native outer membrane vesicle vaccines from mutants engineered to express fHbp variants had broad bactericidal activity against group A, W-135, or X strains. Conclusions. Despite extensive natural exposure of the African population, fHbp is conserved among African strains. A native outer membrane vesicle vaccine that expresses fHbp variants can potentially elicit protective antibodies against strains from all capsular groups that cause epidemics in the region.
引用
收藏
页码:1360 / 1368
页数:9
相关论文
共 51 条
[1]  
[Anonymous], 1991, NIPH ANN
[2]   Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor H-binding protein [J].
Beernink, Peter T. ;
Welsch, Jo Anne ;
Bar-Lev, Michal ;
Koeberling, Oliver ;
Comanducci, Maurizio ;
Granoff, Dan M. .
INFECTION AND IMMUNITY, 2008, 76 (09) :4232-4240
[3]   Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: Implications for the development of a multicomponent group B vaccine [J].
Beernink, Peter T. ;
Welsch, Jo Anne ;
Harrison, Lee H. ;
Leipus, Arunas ;
Kaplan, Sheldon L. ;
Granoff, Dan M. .
JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (10) :1472-1479
[4]   Rapid genetic grouping of factor H-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate [J].
Beernink, Peter T. ;
Leipus, Arunas ;
Granoff, Dan M. .
CLINICAL AND VACCINE IMMUNOLOGY, 2006, 13 (07) :758-763
[5]   Meningococcal genetic variation mechanisms viewed through comparative analysis of serogroup C strain FAM18 [J].
Bentley, Stephen D. ;
Vernikos, George S. ;
Snyder, Lori A. S. ;
Churcher, Carol ;
Arrowsmith, Claire ;
Chillingworth, Tracey ;
Cronin, Ann ;
Davis, Paul H. ;
Holroyd, Nancy E. ;
Jagels, Kay ;
Maddison, Mark ;
Moule, Sharon ;
Rabbinowitsch, Ester ;
Sharp, Sarah ;
Unwin, Louise ;
Whitehead, Sally ;
Quail, Michael A. ;
Achtman, Mark ;
Barrell, Bart ;
Saunders, Nigel J. ;
Parkhill, Julian .
PLOS GENETICS, 2007, 3 (02) :230-240
[6]   EFFECT OF OUTER-MEMBRANE VESICLE VACCINE AGAINST GROUP-B MENINGOCOCCAL DISEASE IN NORWAY [J].
BJUNE, G ;
HOIBY, EA ;
GRONNESBY, JK ;
ARNESEN, O ;
HOLSTFREDRIKSEN, J ;
HALSTENSEN, A ;
HOLTEN, E ;
LINDBAK, AK ;
NOKLEBY, H ;
ROSENQVIST, E ;
SOLBERG, LK ;
CLOSS, O ;
ENG, J ;
FROHOLM, LO ;
LYSTAD, A ;
BAKKETEIG, LS ;
HAREIDE, B .
LANCET, 1991, 338 (8775) :1093-1096
[7]   Meningococcal meningitis:: Unprecedented incidence of serogroup X-related cases in 2006 in Niger [J].
Boisier, Pascal ;
Nicolas, Pierre ;
Djibo, Saacou ;
Taha, Muhamed-Kheir ;
Jeanne, Isabelle ;
Mainassara, Halima Boubacar ;
Tenebray, Bernard ;
Kairo, Kiari Kaka ;
Giorgini, Dario ;
Chanteau, Suzanne .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (05) :657-663
[8]   NadA, a novel vaccine candidate of Neisseria meningitidis [J].
Comanducci, M ;
Bambini, S ;
Brunelli, B ;
Adu-Bobie, J ;
Aricò, B ;
Capecchi, B ;
Giuliani, MM ;
Masignani, V ;
Santini, L ;
Savino, S ;
Granoff, DM ;
Caugant, DA ;
Pizza, M ;
Rappuoli, R ;
Mora, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (11) :1445-1454
[9]  
De Groot Anne S, 2004, Expert Rev Vaccines, V3, P59
[10]   Vaccine potential of the Neisseria meningitidis 2086 lipoprotein [J].
Fletcher, LD ;
Bernfield, L ;
Barniak, V ;
Farley, JE ;
Howell, A ;
Knauf, M ;
Ooi, P ;
Smith, RP ;
Weise, P ;
Wetherell, M ;
Xie, XL ;
Zagursky, R ;
Zhang, Y ;
Zlotnick, GW .
INFECTION AND IMMUNITY, 2004, 72 (04) :2088-2100